The stock of Acadia Pharmaceuticals Incorporated (NASDAQ:ACAD) registered a decrease of 1.04% in short interest. ACAD’s total short interest was 18.77 million shares in September as published by FINRA. Its down 1.04% from 18.97 million shares, reported previously. With 1.59 million shares average volume, it will take short sellers 12 days to cover their ACAD’s short positions. The short interest to Acadia Pharmaceuticals Incorporated’s float is 21.08%. About 522,736 shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has risen 82.83% since February 8, 2016 and is uptrending. It has outperformed by 66.34% the S&P500.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $3.99 billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. It currently has negative earnings. The Company’s lead drug candidate, NUPLAZID , is under development for the treatment of Parkinson’s disease psychosis (PDP).
The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio dropped, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
March Altus Capital Management Lp holds 20.75% of its portfolio in ACADIA Pharmaceuticals Inc. for 82,723 shares. Hwg Holdings Lp owns 289,380 shares or 8.72% of their US portfolio. Moreover, Baker Bros. Advisors Lp has 8.34% invested in the company for 24.52 million shares. The Florida-based Harvey Capital Management Inc has invested 5.73% in the stock. Palo Alto Investors Llc, a California-based fund reported 1.44 million shares.
Out of 2 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. ACADIA Pharmaceuticals has been the topic of 3 analyst reports since November 6, 2015 according to StockzIntelligence Inc. Leerink Swann downgraded the stock on May 3 to “Market Perform” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.